|
End-of-day quote
Other stock markets
|
5-day change | 1st Jan Change | ||
| 1.790 USD | +1.70% |
|
-3.24% | -80.18% |
| 07-16 | EnGene Therapeutics Initiates Planned BLA Submission For Detalimogene Voraplasmid And Provides Updates On LEGEND Phase 2 Trial | CI |
| 07-16 | Engene Therapeutics Inc. Announces Board Changes | CI |
| Market Cap | 120M 105M 98.35M 90.26M 169M 11.49B 173M 1.17B 456M 5.68B 450M 440M 19.65B | P/E 2026 * |
-1.03x | P/E 2027 * | -1.17x |
|---|---|---|---|---|---|
| Enterprise Value | -81.33M -71.46M -66.7M -61.22M -115M -7.79B -117M -791M -309M -3.85B -305M -299M -13.33B | EV / Sales 2026 * |
-
| EV / Sales 2027 * | -1.23x |
| Free-Float |
99.91% | Yield 2026 * |
-
| Yield 2027 * | - |
Last Transcript: enGene Therapeutics Inc.
| 1 day | +1.70% | ||
| 1 week | -3.24% | ||
| Current month | +3.47% | ||
| 1 month | +0.56% | ||
| 3 months | -74.57% | ||
| 6 months | -82.57% | ||
| Current year | -80.18% |
| 1 week | 1.71 |  | 1.89 |
| 1 month | 1.71 | | 1.96 |
| Current year | 1.4 | | 12.25 |
| 1 year | 1.4 | | 12.25 |
| 3 years | 1.4 | | 47.17 |
| 5 years | 1.4 | | 47.17 |
| 10 years | 1.4 | | 47.17 |
| Manager | Title | Age | Since |
|---|---|---|---|
Ronald Cooper
CEO | Chief Executive Officer | 63 | 2024-07-21 |
Anthony Cheung
CTO | Chief Tech/Sci/R&D Officer | 55 | 2023-04-23 |
Kathleen Richton
DFI | Director of Finance/CFO | 48 | 2026-07-15 |
| Director | Title | Age | Since |
|---|---|---|---|
Gerry Brunk
BRD | Director/Board Member | 57 | 2023-08-07 |
Lota Zoth
BRD | Director/Board Member | 66 | 2023-12-17 |
Paul Hastings
BRD | Director/Board Member | 66 | 2024-05-14 |
| Date | Insider | Type | Main position | Quantity | % Market Cap. | |
|---|---|---|---|---|---|---|
| 7/16/26 | Other | Interim Chief Business Officer | 75,000 | 0.1120% | ||
| 7/16/26 | Other | Chief Financial Officer | 170,800 | 0.2550% | ||
| 6/16/26 | Option | Chief Technology Officer | 31,000 | 0.0463% |
| Change | 5-day change | 1-year change | 3-year change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | +1.70% | -3.24% | -48.12% | -83.41% | 118M | |
| +0.47% | +2.27% | +50.78% | +70.84% | 55.01B | |
| +2.83% | +0.48% | +28.18% | +82.59% | 54.24B | |
| +0.54% | +1.22% | -16.62% | -13.47% | 23.38B | |
| -0.97% | -3.30% | -1.79% | +383.00% | 22.57B | |
| +0.25% | +1.39% | +17.20% | -9.05% | 20.19B | |
| -2.15% | -2.30% | +27.27% | -31.03% | 17.86B | |
| -2.14% | -3.75% | +26.23% | +536.72% | 15.5B | |
| -3.14% | -8.47% | +165.37% | +292.18% | 14.2B | |
| -2.09% | +0.64% | +49.78% | +178.74% | 14.2B | |
| Average | -0.29% | -1.03% | +29.83% | +140.71% | 23.73B | |
| Weighted average by Cap. | +0.28% | -0.11% | +34.49% | +130.51% |
| 2026 * | 2027 * | |
|---|---|---|
| Net sales | - | 6.17M 5.42M 5.06M 4.64M 8.69M 591M 8.91M 60.01M 23.47M 292M 23.17M 22.66M 1.01B |
| Net income | -119M -104M -97.37M -89.36M -167M -11.37B -171M -1.15B -452M -5.63B -446M -436M -19.45B | -119M -104M -97.49M -89.47M -167M -11.38B -172M -1.16B -452M -5.63B -446M -437M -19.47B |
| Net Debt | -201M -177M -165M -151M -284M -19.28B -291M -1.96B -765M -9.54B -756M -739M -32.97B | -127M -112M -105M -95.96M -180M -12.21B -184M -1.24B -485M -6.04B -479M -468M -20.89B |
| Date | Price | Change | Volume |
|---|---|---|---|
| 26-07-29 | US$1.790 | +1.70% | 559,027 |
| 26-07-28 | US$1.760 | 0.00% | 582,867 |
| 26-07-27 | US$1.760 | -3.30% | 651,327 |
| 26-07-24 | US$1.820 | -3.70% | 665,841 |
| 26-07-23 | US$1.890 | +2.16% | 1,659,521 |
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Stocks
- ENGN Stock
Select your edition
All financial news and data tailored to specific country editions
